On November 12, 2024, Rebecca Chambers, Chief Financial Officer of Veracyte Inc (VCYT, Financial), executed a sale of 15,275 shares of the company. The transaction was filed with the SEC and can be viewed in detail through this SEC Filing. Following this transaction, the insider now owns 124,501 shares of Veracyte Inc.
Veracyte Inc (VCYT, Financial) specializes in genomic diagnostics and is known for its advanced tests that help in the diagnosis of thyroid cancer, lung cancer, and other diseases. The company's goal is to reduce unnecessary surgeries and healthcare costs by providing accurate, non-invasive diagnostic tests.
Over the past year, the insider transaction history at Veracyte Inc shows a total of 17 insider sells and no insider buys. This recent transaction by Rebecca Chambers aligns with the ongoing trend of insider sales at the company.
Shares of Veracyte Inc were priced at $38.34 on the day of the transaction. The company has a market cap of approximately $2.87 billion. According to the GF Value, the intrinsic value estimate of the stock is $32.20, indicating that the stock is modestly overvalued with a price-to-GF-Value ratio of 1.19.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from analysts.
This sale by the insider may be of interest to current and potential investors, providing insight into the insider's perspective on the stock's valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
